产品封面图

Anti-Human CD80/B7-1 Antibody

(IDEC-114), PerCP
收藏
  • 询价
  • abinscience
  • France
  • HW630147
  • 2025年07月12日
  • Human
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 亚型

      IgG1, lambda

    • 形态

      Liquid

    • 保存条件

      0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

    • 克隆性

      Monoclonal

    • 标记物

      PerCP

    • 适应物种

      Human

    • 保质期

      1 year

    • 抗原来源

      Mouse

    • 目录编号

      HW630147

    • 级别

      科研级别

    • 库存

      999

    • 供应商

      abinscience

    • 浓度

      1mg/ml

    • 抗体英文名

      Anti-Human CD80/B7-1 Antibody (IDEC-114), PerCP

    • 抗体名

      Anti-Human CD80/B7-1 Antibody (IDEC-114), PerCP

    • 规格

      100ug

    产品细节图片1

    Product nameAnti-Human CD80/B7-1 Antibody (IDEC-114), PerCP
    Catalog No.HW630147
    Host speciesMouse
    Specificity\
    ConjugationPerCP
    Species reactivityHuman
    Immunogen\
    FormLiquid
    Storage buffer0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
    Purity\
    ClonalityMonoclonal
    IsotypeIgG1, lambda
    ApplicationsFCM
    TargetCD80, BB1, T-lymphocyte activation antigen CD80, CD28LG, B7, CD28LG1, LAB7, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1
    Purification\
    AccessionP33681
    Stability and StorageStore at 4°C for 12 months. Protect from light. Do not freeze.
    Background\
    Alternative Names\
    Clone ID\
    Species\
    NoteFor research use only.

    Abinscience, founded in 2023 and located in the innovation technology center in Strasbourg, France, is the core research reagent brand of ProteoGenix. Focusing on the development and production of life science research reagents, Abinscience takes "Empowering Bioscience Discovery" as its vision, and is committed to providing high-quality and innovative biological reagent products and technical solutions for global researchers.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 【翻译】Development trends for monoclonal antibody cancer therapeutics

      ). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989

    • Immunohistochemistry using Anti-Ganglioside Antibodies

      , T., Terashima,T., and Tai, T.(1993) Generation of a monoclonal antibody specific for ganglioside GM4: evidence for GM4 expression on astrocytes in chicken cerebellum. J. Biochem.(Tokyo), 114 :5-8 3) Kotani, M., Kawashima, I., Ozawa, H., Ogura

    • 双特异抗体(Bispecific antibody)的简介和制作方法

      throughgrafting of complementarity determining regions (CDRs) or using various technologies for recovery of fully human antibodies, such as phage display libraries or transgenic mice expressing human antibody repertoires. Reduced immunogenicity of antibodies

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥708
    普健生物(武汉)科技有限公司
    2025年07月11日询价
    ¥864
    武汉益普生物科技有限公司
    2025年12月10日询价
    ¥500
    北京百奥创新科技有限公司
    2025年07月11日询价
    ¥2676
    武汉佰乐博生物技术有限公司
    2025年07月12日询价
    Anti-Human CD80/B7-1 Antibody (IDEC-114), PerCP
    询价